Industry: Healthcare - Biopharmaceutical Region: Europe Transaction Price: US $1million Transaction Method: Equity investment
The Company is a global biopharmaceutical company focused on the development and commercialization of treatments for patients with genetic, metabolic and life-threatening diseases, as well as medical solutions for the general population. Committed to transforming scientific concepts and breakthroughs into commercial products.
Details:
The Company is a global biopharmaceutical company focused on the development and commercialization of treatments for patients with genetic, metabolic and life-threatening diseases, as well as medical solutions for the general population. Committed to transforming scientific concepts and breakthroughs into commercial products. They are committed to excellence in scientific research and development, building on their global expertise to deliver life-long care and new products to patients and consumers. They focus on the research and development of genetic metabolism and unsolved diseases, aiming to provide innovative medical solutions to complex problems. The company focuses on the development and delivery of treatments for patients with a range of serious genetic and skin disorders. The focus is on the development and commercialization of a drug for the treatment of erythropoietic protoporphyria. As a prophylactic therapy, it provides patients with erythropoietic protoporphyria with the aim of preventing skin symptoms associated with exposure to harmful ultraviolet radiation and treating skin repigmentation caused by several types of depigmentation. The company is also focused on a combination therapy of narrow-band ultraviolet light for patients with vitiligo. Its pipeline includes research and development of pediatric formulations for proprietary innovative drugs; For use in adults with vitiligo, for use with melanocortin analogues and tiny melanopeptides as well as a range of over-the-counter drugs for general photoprotective applications. The company currently has two innovative drugs licensed in the United States and Europe, one in Phase 3 and one in Phase 2. First, the company is seeking a Chinese licence to sell 10 per cent of its stake or products in return for foreign currency investments of about Rmb500m.